Scottish patients placed at the heart of a multi-million pound study of weight-loss medicines.

University of Glasgow, pharmaceutical firm Novo Nordisk and IQVIA, a leading global provider of clinical research services, selected to plan and deliver the research involving 3,000 to 5,000 people from across Scotland.

Findings of the study will provide real-world insight into the lives of people living with obesity and health inequalities across the UK.

Thousands of people from across some of Scotland’s most deprived communities will be invited to take part in groundbreaking research, looking at the real-world impact of weight-loss medicines, thanks to backing from the UK government announced today (Saturday 1 November).

The Scotland CardioMetabolic Impact Study ( SCoMIS ), representing a

See Full Page